Commerce Bank Acquires Shares of 17,206 Halozyme Therapeutics, Inc. $HALO

Commerce Bank acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 17,206 shares of the biopharmaceutical company’s stock, valued at approximately $1,347,000.

Several other large investors have also recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership boosted its stake in Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after buying an additional 749,484 shares during the last quarter. William Blair Investment Management LLC bought a new stake in Halozyme Therapeutics in the 2nd quarter worth approximately $196,540,000. Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after acquiring an additional 25,731 shares during the last quarter. Norges Bank purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter worth approximately $128,201,000. Finally, Federated Hermes Inc. raised its holdings in shares of Halozyme Therapeutics by 8.5% during the 4th quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock worth $105,972,000 after acquiring an additional 123,917 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $79,987,320.40. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 64,103 shares of company stock valued at $5,226,496. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $109.32 on Wednesday. The stock has a market cap of $12.41 billion, a price-to-earnings ratio of 32.63, a price-to-earnings-growth ratio of 0.44 and a beta of 0.85. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The stock has a 50 day moving average price of $84.73 and a 200-day moving average price of $74.19. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $109.55.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.Halozyme Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts expect that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on HALO shares. UBS Group reissued a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Finally, HC Wainwright upped their target price on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.